Fortis Healthcare to buy 51% stake in RHT unit for Rs 970 cr

Published On 2016-02-05 04:13 GMT   |   Update On 2016-02-05 04:13 GMT

New Delhi: Fortis Healthcare  said it will acquire 51 per cent stake in Fortis Hospotel Ltd, a subsidiary of Religare Health Trust (RHT), for Rs 970 crore.RHT is a business trust listed on the SGX of which Fortis is a sponsor with a 28 per cent equity stake."The net investment consideration for the transaction is estimated to be an amount of approximately Rs 970 crore. The economic impact...

Login or Register to read the full article
New Delhi: Fortis Healthcare  said it will acquire 51 per cent stake in Fortis Hospotel Ltd, a subsidiary of Religare Health Trust (RHT), for Rs 970 crore.

RHT is a business trust listed on the SGX of which Fortis is a sponsor with a 28 per cent equity stake.

"The net investment consideration for the transaction is estimated to be an amount of approximately Rs 970 crore. The economic impact to Fortis would be lower as Fortis owns 28 per cent equity stake in RHT," Fortis Healthcare said in a statement.

Commenting on the development, Fortis Healthcare Executive Chairman Malvinder Singh said: "RHT will continue to be a strategic vehicle for our asset light growth in India and will play a larger role in our India centric expansion plans going forward."

With a potential to double the existing bed capacity from the current approximately 4,500 beds, "RHT will undertake a majority of the investments for all our brownfield and bolt on expansion plans in all the clinical establishments in its portfolio," he added.

The investment payable will be funded largely through internal accruals. "As a result of the majority acquisition of FHTL, it will become a subsidiary of Fortis and hence be consolidated with Fortis," Fortis Healthcare said.

The transaction is on an arm's length basis with an independent valuation done by valuers of international repute both by Fortis and RHT respectively, it added.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News